Abstract:Abstract Background Acute gouty is caused by the excessive accumulation of Monosodium Urate (MSU) crystals within various parts of the body, which leads to a deterioration of the local microenvironment. This degradation is marked by elevated levels of uric acid (UA), increased reactive oxygen species (ROS) production, hypoxic conditions, an upsurge in pro-inflammatory mediators, and mitochondrial dysfunction. Results In this study, we developed a multifunctional nanoparticle of polydopamine-platinum (PDA@Pt) to combat acute gout by leveraging mild hyperthermia to synergistically enhance UA degradation and anti-inflammatory effect. Herein, PDA acts as a foundational template that facilitates the growth of a Pt shell on the surface of its nanospheres, leading to the formation of the PDA@Pt nanomedicine. Within this therapeutic agent, the Pt nanoparticle catalyzes the decomposition of UA and actively breaks down endogenous hydrogen peroxide (H 2 O 2 ) to produce O 2 , which helps to alleviate hypoxic conditions. Concurrently, the PDA component possesses exceptional capacity for ROS scavenging. Most significantly, Both PDA and Pt shell exhibit absorption in the Near-Infrared-II (NIR-II) region, which not only endow PDA@Pt with superior photothermal conversion efficiency for effective photothermal therapy (PTT) but also substantially enhances the nanomedicine’s capacity for UA degradation, O 2 production and ROS scavenging enzymatic activities. This photothermally-enhanced approach effectively facilitates the repair of mitochondrial damage and downregulates the NF-κB signaling pathway to inhibit the expression of pro-inflammatory cytokines. Conclusions The multifunctional nanomedicine PDA@Pt exhibits exceptional efficacy in UA reduction and anti-inflammatory effects, presenting a promising potential therapeutic strategy for the management of acute gout. Graphical Abstract

HQL6 Serves As a Novel P2Y14 Receptor Antagonist to Ameliorate Acute Gouty Arthritis Through Inhibiting Macrophage Pyroptosis.

Discovery of Novel and Potent P2Y14R Antagonists Via Structure-Based Virtual Screening for the Treatment of Acute Gouty Arthritis

Z1456467176 Alleviates Gouty Arthritis by Allosterically Modulating P2X7R to Inhibit NLRP3 Inflammasome Activation

Design, Synthesis and Evaluation of 3-Amide-5-aryl Benzoic Acid Derivatives As Novel P2Y14R Antagonists with Potential High Efficiency Against Acute Gouty Arthritis.

Discovery and Computational Studies of 2-Phenyl-benzoxazole Acetamide Derivatives As Promising P2Y14R Antagonists with Anti-Gout Potential

GPR105-Targeted Therapy Promotes Gout Resolution As a Switch Between NETosis and Apoptosis of Neutrophils.

Identification of O-arylated huperzinines as novel cholinergic anti-inflammatory pathway agonists against gout arthritis

Development of a novel anti-inflammatory recombinant uricase with extended half-life for gout therapy

P2Y6 Receptor Antagonist MRS2578 Inhibits Neutrophil Activation and Aggregated Neutrophil Extracellular Trap Formation Induced by Gout-Associated Monosodium Urate Crystals

Discovery of a potent, Highly selective, and In vivo anti-inflammatory Efficacious, P2Y 6 R antagonist with a novel quinoline-pyrazole scaffold

Discovery of a Potent and Orally Bioavailable Xanthine Oxidase/Urate Transporter 1 Dual Inhibitor as a Potential Treatment for Hyperuricemia and Gout

Discovery of Selective P2Y6R Antagonists with High Affinity and in Vivo Efficacy for Inflammatory Disease Therapy

Biomimetic Integrated Nanozyme for Flare and Recurrence of Gouty Arthritis

Novel Leflunomide Analog, UTLOH-4e, Ameliorates Gouty Arthritis Induced by Monosodium Urate Via NF-κB/NLRP3 Signaling Pathway

Targeting BRD4 Prevents Acute Gouty Arthritis by Regulating Pyroptosis

P2Y14 Receptor Has a Critical Role in Acute Gouty Arthritis by Regulating Pyroptosis of Macrophages

Development of Novel NLRP3-XOD Dual Inhibitors for the Treatment of Gout.

P2X7R Mediates the Synergistic Effect of ATP and MSU Crystals to Induce Acute Gouty Arthritis

Mild hyperthermia enhanced synergistic uric acid degradation and multiple ROS elimination for an effective acute gout therapy

Design, Synthesis and Biological Activity Evaluation of Novel URAT1 Inhibitors

Identification of N-phenyl-N-(quinolin-4-yl) Amino Carboxylic Acids As URAT1 Inhibitors with Hypouricemic Effects